AAM Urges Congress To Re-evaluate Blocking Act
Report Claims Legislation Could Cost $1.7bn For Each Generic Delayed
Pointing out the “critical shortcomings of the Blocking Act” in a new report, the AAM has urged the US Congress to re-evaluate the legislation.
You may also be interested in...
Ending the “gaming of regulatory and patent processes by drug makers to unfairly protect monopolies”, advancing biosimilars and generics to encourage greater competition and offering free generics to low-income seniors are among the measures set out in a “blueprint to lower drug prices” that has just been announced by US President Donald Trump. Billing the reform as “the most sweeping action in history to lower the price of prescription drugs for the American people”, Trump said his administration would be “eliminating the middlemen” and targeting ‘freeloading’ other countries.
Armas has kicked off 2020 with the launch of four generic injectables in the US.
While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.